STOCKS TELEGRAPH

Tag: ACAD stock

  • Acadia Pharmaceuticals Inc Sees Positive Shift in Analysts Rating

    Acadia Pharmaceuticals Inc Sees Positive Shift in Analysts Rating

    The biopharmaceutical industry is in constant flux, with companies’ stock prices often being impacted by analysts’ ratings.

    JP Morgan issued an upgrade for the stock, shifting their rating from ‘Neutral’ to ‘Overweight.’ Alongside this positive change in sentiment, the investment bank also raised its price target for the stock from $29 to $32.

    This upgrade reflects a more bullish outlook on the US stocks performance and suggests that JP Morgan sees greater potential for price appreciation in the future.

    Understanding Analysts Rating Upgrade Before diving into the specifics of Acadia Pharmaceuticals Inc’s rating upgrade, it’s crucial to understand what an analyst’s rating upgrade means in the financial world.

    Acadia Pharmaceuticals Inc – Recent Performance

    In the recent trading session, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) demonstrated significant positive movement. When the market closed, the stock settled at $23.42, reflecting a notable increase of $1.68, which translated to a 7.73% surge throughout the day.

    Additionally, during after-hours trading at 12:01 AM, the stock sustained this optimistic trend, trading at $23.50, showing a modest uptick of $0.08, or 0.34%.

    Reasons Behind the Upgrade

    The reasons behind an analyst rating upgrade can vary, but they often include strong financial performance, positive industry trends, or promising developments within the company.

    For Acadia Pharmaceuticals Inc, the specific reasons behind JP Morgan’s upgrade have not been publicly disclosed.

    Other Recent Development

    In another recent development within ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), it was reported that on October 6, 2023, the company’s Executive Vice President, General Counsel, and Secretary, Austin Kim, divested a total of 16,369 shares.

    This transaction is just one among several insider transactions that have been unfolding over the past year at ACADIA Pharmaceuticals Inc., highlighting the ongoing activity among company insiders.

    Conclusion

    The recent upgrade in rating for Acadia Pharmaceuticals Inc by JP Morgan analysts highlights the company’s strong potential in the biopharmaceutical sector.

    This upgrade, coupled with the increase in the stock’s price target, has resulted in a positive shift in the company’s stock performance, making it a stock to watch in the coming months.

  • Acadia Pharmaceuticals Inc. (ACAD) Slides Further pre-Market on Missed Pain-Therapy Trial Main Goals

    On April 18, Acadia Pharmaceuticals Inc. (ACAD) shared that its acute postoperative pain therapy trial did not meet its primary endpoint. The disappointing news caused ACAD stock to plunge down by a further 6.34% in the pre-market. The stock was already trading in the red with a loss of 4.52% during the regular session. Thus, with the further decline pre-market, the stock then reached a value of $20.99 per share, on Tuesday.

    Source: Zapier

    ACAD’s ACP-044 Trial Results

    On Monday, the company announced top-line results from the Phase 2 study of ACP-044. ACP-044 is a non-opioid investigational drug currently under development for acute and chronic pain treatment.

    The study was evaluating the efficacy and safety of the therapy for the treatment of acute postoperative pain following bunionectomy surgery. Two doses of ACP-044; 1600 mg once daily and 400 mg four times daily were being evaluated against a placebo. The primary endpoint of the trial was a comparison of cumulative pain intensity scores over 24 hours against a placebo.

    While the once-daily group completely failed to meet the primary endpoint, the other group did show a slight favorite on the endpoint. But the numerical trends while being better than the placebo were still not statistically significant at 48 and 72 hours.

    Additionally, ACO-044 is currently being evaluated in a study on osteoarthritis.

    Market Overview

    Central Nervous System therapeutics include therapies for pain management, dementia, Alzheimer’s, Parkinson’s, Multiple Sclerosis, and other disorders. The global CNS therapeutics market is forecasted to grow at a CAGR of 9.05% to reach $168.43 billion by 2028 from $84.24 billion in 2020.

    The frequency of mental illness and life-style related CNS disorders is increasing day by day. Moreover, rising awareness regarding psychiatric diseases and the growing elderly population are also contributing to the growth of the market. Pain management being an important part of the market is largely an unmet need. Most of the existing treatments for pain management include addictive therapies like opioids which come with their own share of drawbacks.

    ACAD’s Analysis and Outlook

    After resubmitting sNDA for pimavanserin for Alzheimer’s psychosis to the FDA, ACAD is now planning n submitting NDA for trofinetide for Rett syndrome this year. While the ACP-044 failed to show benefit in acute pain management study, its study in osteoarthritis is ongoing. The company expected the study to be completed in H1 2022.

    For fiscal 2022, the company expected NUPLAZID net sales to be $510-$560 million with R&D expenses of $355-$375 million. Furthermore, SG&A expenses for the year are projected to be $360-$380 million.

  • ACADIA Pharmaceuticals Inc. (ACAD) Stock Rocketing Higher in Aftermarket, Here’s the Reason

    ACADIA Pharmaceuticals Inc. (ACAD) Stock Rocketing Higher in Aftermarket, Here’s the Reason

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company, has soared 21.80% in aftermarket trading session. Consequently, ACAD stock is trading at $23.63 at the time of the writing. On Monday, ACAD stock closed the day at $19.40 after gaining an increase of 3.25% during regular trading hours. The increase in ACAD stock could be attributed to the positive topline results from the phase 3 Lavender trial.

    Why ACAD on a Rise?

    On Monday, ACAD announced the positive topline results from the pivotal phase-3 Lavender study. The study highlighted the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome. The placebo-controlled study was conducted for 12 week period and it demonstrated significantly improved results over the placebo for both the co-primary endpoints. The change in the Rett Syndrome Behaviour Questionnaire (RSBQ) from baseline to week 12 was -5.1 vs. -1.7.

    Q3 2021 Operational Results

    On 8th November, ACAD released the operational results for the third quarter of the fiscal year 2021. The quarter ended on 30th September 2021. The company generated total revenue of $131.1 million during the period against $120.5 million for the same period of 2020. The total operating expenses for the period were $146.9 million against $206.4 million for the same period of 2020. The net loss suffered by the company during the three months was $14.4 million (or $0.09 per basic and diluted share) against $84.6 million (or $0.54 per basic and diluted share) for the same period of 2020.

    Executive Commentary

    Steve Davis, Chief Executive Officer of ACAD, while commenting on the results said that the company’s performance during the third quarter depicts the volume growth across all of the channels. Its strong relative performance highlights the ability of its commercial team to drive the sales of its products in challenging circumstances. He hoped that the company is looking forward to meeting some extremely important goals during the upcoming few weeks.  

    Future Outlook for ACAD

    The last three months have seen ACAD stock surge more than 19%. That’s good news for the investors of Acadia because looking at the company appears to be well on track to success after a gruesome 12 month period, in which its stock value declined more than 60%. Potential investors should keep a close eye on the performance of ACAD stock during the upcoming months.

  • Acadia Pharmaceuticals Inc. (ACAD) stock declines in the pre market trading. Let’s find out why?

    Acadia Pharmaceuticals Inc. (ACAD) stock declined by 14.42% in the pre market trading session after Acadia Pharmaceuticals has received a response letter from FDA for its supplement new drug application (sNDA). Acadia is breaking new ground in neuroscience to improve people’s lives. ACAD has been at the forefront of healthcare for over 25 years, bringing critical ideas to those who need them most. We developed and marketed the first and only FDA-approved treatment for hallucinations and delusions associated with psychosis caused by Parkinson’s disease.

    What is happening?

    The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to Acadia Pharmaceuticals addressing its supplementary New Drug Application (sNDA) for NUPLAZID, which is used to treat hallucinations and delusions associated with dementia-related psychosis. In their response, FDA mentioned that they had finished reviewing the application and sent a CRL, while concluded that it could not be accepted in its current state.

    According to the previous agreements with the Division of Psychiatry regarding the pivotal Phase 3 HARMONY study design, which sought to examine a large DRP patient population as a single group, the Division identified a lack of statistical significance in some dementia subgroups and inadequate numbers of patients with some less common dementia subtypes as lack of significant evidence of efficacy in order to support the approval.

    The pivotal HARMONY trial for the DRP reached its preset primary and secondary endpoints, demonstrating pimavanserin’s clinical and statistical superiority over placebo, which was a prerequisite for the DRP indication. The predefined criteria did not include statistical separation by dementia subgroups or a minimum number of patients with distinct subtypes.

    Conclusion

    With ACAD’s new drug application sNDA not getting approved, it is quite possible that the stock price has declined following this disapproval. Although ACAD is working to find its way out with the cooperation of FDA to get the approval but for now it has become a matter of disinterest for investors and therefore they are not making any bets in ACAD stock.